Vir Biotechnology appoints Timothy Coughlin as new director and Audit Committee Chair

Vir Biotechnology, Inc.

Board increased from 7 to 8 members; Timothy Coughlin appointed effective June 9, 2026.
Coughlin named Chair of the Audit Committee immediately upon appointment.
Will receive standard non-employee director cash and equity per company policy; no related-party transactions.
Received automatic stock option and RSU awards under the 2019 Equity Incentive Plan.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Timothy Coughlin

Director and Chair of the Audit Committee

VIR · Vir Biotechnology, Inc.

Effective: 2026-06-09
Filed: June 10, 2026, 4:27 PM ET

the appointment of Timothy Coughlin, CPA, to fill the newly created vacancy and serve on the Board as a Class III director until the Company's 2028 annual meeting of stockholders, as well as the appointment of Mr. Coughlin as Chair of the Audit Committee of the Board, in each case effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Timothy Coughlin was appointed as Director and Chair of the Audit Committee at Vir Biotechnology, Inc..

Action: appointed
Role: Director and Chair of the Audit Committee

Exact text from the filing

the appointment of Timothy Coughlin, CPA, to fill the newly created vacancy and serve on the Board as a Class III director until the Company's 2028 annual meeting of stockholders, as well as the appointment of Mr. Coughlin as Chair of the Audit Committee of the Board, in each case effective immediately.

View on SEC.gov

Vir Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-042237

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.